Dr. Elam R Stoltzfus, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 55 Medical Park Dr, Lewisburg, PA 17837 Phone: 570-523-3264 Fax: 570-523-3465 |
Shalini Khurana, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 55 Medical Park Dr, Lewisburg, PA 17837 Phone: 570-523-3264 Fax: 570-523-3465 |
Dr. Jay Marlin Nissley, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 55 Medical Park Dr, Lewisburg, PA 17837 Phone: 570-523-3264 Fax: 570-523-3465 |
Dr. David M Castellan, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 55 Medical Park Dr, Lewisburg, PA 17837 Phone: 570-523-3264 Fax: 570-523-3465 |
Dr. Eric J. Schuck, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 55 Medical Park Dr, Lewisburg, PA 17837 Phone: 570-523-3264 Fax: 570-523-3475 |
Dr. Mary Beth Ann O'hara, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 121 Jpm Rd, Lewisburg, PA 17837 Phone: 570-551-0300 |
Dr. Shakuntala Y Varhade, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 55 Medical Park Dr, Lewisburg, PA 17837 Phone: 570-523-3264 Fax: 570-523-3465 |
Dr. Dino J. Baca, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Hospital Dr, Lewisburg, PA 17837 Phone: 570-522-4260 Fax: 570-768-3704 |
Dr. Margaret M. Still, D.O. Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 250 Reitz Blvd, Lewisburg, PA 17837 Phone: 570-523-0055 Fax: 570-523-7996 |
News Archive
A new drug candidate previously shown to reduce harmful side effects of the autoimmune disease lupus also may be useful in treating psoriasis.
Popular Mechanics has recognized three NSF-funded projects with innovation Breakthrough Awards: an artificial retina returning sight to those who have lost it; a system that uses "controlled rocking" and energy-dissipating fuses to help buildings withstand earthquakes; and an inexpensive medical microscope built for cell-phones that allows doctors in rural villages to identify malaria-infected blood cells.
Future medicine is bound to include extensive tissue-engineering technologies such as organs-on-chips and organoids - miniature organs grown from stem cells. But all this is predicated on a simple yet challenging task: controlling cellular behavior in three dimensions.
Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.
› Verified 2 days ago